Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

By sjmartinez • March 3, 2023

Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, Carrato A, Zhang Y, Liu K, Cha E, Keegan A, Bhatta S, Strassburg CP, Roohullah A. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO Open. 2023 Feb 28;8(2):100884. doi: 10.1016/j.esmoop.2023.100884. Epub ahead of print. PMID: 36863095.

Tags: breast neoplasms, drug therapy combination, Gastrointestinal neoplasms, Hematology/Oncology, Publications, viral immunotherapy, virotherapy

“Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and reality

Sedrak MS, Ramalingam SS, Sparano JA. "Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and reality. Cancer. 2026 Jul 1;132(13):e70499.[...]

Case Report: A case of HIV seroconversion in a high-risk individual after 35 years of resistance with a CCR5DELTA32 heterozygous genotype

Aziz N, Kim EY, Jamieson BD, Mimiaga MJ, Martinez J, Detels R. Case Report: A case of HIV seroconversion in a high-risk individual after 35[...]

Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer

Tsvetkova O, Gil TE, Kassir G, Castanon S, Kollapaneni SS, Han A, Park SJ, Li R, Velez MA, Lisberg AE. Evaluating datopotamab deruxtecan (Dato-DXd) as[...]